On November 19, 2024, Joseph Mccracken, a Director at Savara Inc (SVRA, Financial), purchased 20,000 shares of the company. Following this transaction, the insider now holds a total of 210,837 shares. The purchase was documented in a SEC Filing.
Savara Inc is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company's lead product candidate, molgramostim, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
The insider's recent acquisition is part of a broader trend observed over the past year, where Joseph Mccracken has purchased a total of 20,000 shares and sold none. In the same period, Savara Inc has seen 2 insider buys and 3 insider sells.
Shares of Savara Inc were trading at $2.95 each on the day of the purchase, resulting in a market cap of $504.560 million for the company.
For investors, insider buying can be a signal of confidence in the company's future prospects. However, it is essential to consider other factors such as the company's GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow when evaluating investment opportunities.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
